Quick Search 
Drugs of Today
Register or sign in

  
 
  
Drugs Today 2015, 51(7): 415
ISSN 1699-3993
Copyright 2015 Clarivate
CCC: 1699-3993
DOI: 10.1358/dot.2015.51.7.2361328
 
 
Hydrocodone bitartrate for chronic pain
Manchikanti, L., Atluri, S., Kaye, A.M., Kaye, A.D.
 
 
Hydrocodone bitartrate is the most commonly used drug for acute and chronic pain in the U.S. with over 135 million prescriptions in 2012. The U.S. is the primary consumer of hydrocodone, using 99% of the global supply for 4.4% of the global population. With its easy availability and abuse patterns, hydrocodone has been touted as a primary driver of opioid-related abuse and misuse. There are no clinical efficacy studies of hydrocodone in short-acting form in combination with acetaminophen or ibuprofen in chronic pain. Hydrocodone has been approved with two long-term formulations since 2014. The FDA has rescheduled hydrocodone from Schedule III to Schedule II which went into effect on October 6, 2014, along with a limit on added acetaminophen of 325 mg for each dose of hydrocodone. This review examines the evolution of hydrocodone into a common and yet controversial drug in the U.S. with its pharmacokinetics, pharmacodynamics, safety and efficacy.


Full Text: PDF 
 
  



© Clarivate. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie Policy